Is a 50% improvement threshold adequate to justify progression from sacral neuromodulation testing to implant?

Area of Science:

• Urology
• Neurology
• Medical Devices

Background:

• Sacral neuromodulation (SNM) is a treatment for overactive bladder.
• Current criteria for SNM implantation (SNM-II) involve a ≥50% improvement during SNM testing (SNM-I).
• Long-term efficacy of SNM can decrease over time, but the relationship with initial symptom reduction is unclear.

Purpose of the Study:

• To determine if the degree of symptom improvement after SNM-I predicts long-term success of SNM-II.
• To investigate if a higher improvement threshold during SNM-I could be a better indicator for sustained efficacy.

Main Methods:

• Retrospective review of patients undergoing SNM for overactive bladder.
• Patients were categorized into two groups based on SNM-I improvement: 50%-75% (Group 1) and >75% (Group 2).
• Clinical variables and long-term device efficacy (mean follow-up 46 months) were compared.

Main Results:

• Of 137 patients implanted, 55% reported 50%-75% improvement (Group 1) and 45% reported >75% improvement (Group 2).
• Long-term device efficacy was significantly higher in Group 2 (68%) compared to Group 1 (44%) (p=0.007).
• Baseline stress urinary incontinence and >75% SNM-I improvement predicted long-term success.

Conclusions:

• A greater than 75% symptom reduction during SNM-I is associated with a higher likelihood of maintaining device efficacy long-term.
• The current 50% improvement threshold for SNM-II may need re-evaluation.
• Further research is needed to confirm if increasing the SNM-I threshold improves patient outcomes.